Synthesis and biological characterization of 1,4,5,6- tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists

Journal of Medicinal Chemistry

Volumn 40, Issue 8, 1997, Pages 1230-1246

  Messer Jr , William S ^a   Abuh, Yahaya F ^a   Liu, Yang ^a   Periyasamy, Sumudra ^a   Ngur, Dan O ^a   Edgar, Michael A N ^a,b   El Assadi, Afif A ^a   Sbeih, Sbeih ^a   Dunbar, Philip G ^a,c   Roknich, Scott ^a   Rho, Taikyun ^a   Fang, Zheng ^a   Ojo, Babatunde ^a,d   Zhang, Hao ^a,e   Huzl III, James J ^a   Nagy, Peter I ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c WASHINGTON STATE UNIVERSITY   (United States)

^d GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,5,6 TETRAHYDROPYRIMIDINE DERIVATIVE; 2 AMINO 3,4,5,6 TETRAHYDROPYRIDINE DERIVATIVE; ACETYLCHOLINE; ADENYLATE CYCLASE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING SITE; COGNITIVE DEFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; RAT;

ANIMALS; ARECOLINE; BRAIN; CARBACHOL; CELL LINE; MODELS, MOLECULAR; MUSCARINIC AGONISTS; PHOSPHATIDYLINOSITOLS; PYRIMIDINES; QUINUCLIDINYL BENZILATE; RATS; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M3; RECEPTORS, MUSCARINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 15444354604     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960467d     Document Type: Article

References (70)

1. Davies, P.; Maloney, A. J. F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, No. 2, 1403.
2. Whitehouse, P. J.; Martino, A. M.; Antuono, P. G.; Lowenstein, P. R.; Coyle, J. T.; DeLong, M. R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982, 215, 1237-1239.
3. Coyle, J. T.; Price, D. L.; DeLong, M. R. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983, 219, 1184-1190.
4. Soininen, H.; Kosunen, O.; Helisalmi, S.; Mannermaa, A.; Paliärvi, L.; Talasniemi, S.; Ryynänen, M.; Riekkinen, P., Sr. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein ∈4 allele. Neurosci. Lett. 1995, 187, 79-82.
5. Christie, J. E.; Shering, A.; Ferguson, J.; Glen, A. I. M. Physostigmine and arecoline. Effects of intravenous infusions in Alzheimer presenile dementia. Br. J. Psychiatry 1981, 138, 46-50.
6. Summers, W. K.; Majovski, L. V.; Marsh, G. M.; Tachiki, K.; Kling, A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N. Engl. J. Med. 1986, 315, 1241-1245.
7. Hollander, E.; Mohs, R. C.; Davis, K. L. Cholinergic approaches to the treatment of Alzheimer's disease. Br. Med. Bull. 1986, 42, 97-100.
8. Moos, W.; Davis, R. E.; Schwarz, R. D.; Gamzu, E. R. Cognition activators. Med. Res. Rev. 1988, 8, 353-391.
9. 3H]-pirenzepine. Life Sci. 1984, 34, 1395-1402.
10. Mash, D. C.; Potter, L. T. Autoradiographic localization of M1 and M2 muscarine receptors in the rat brain. Neuroscience 1986, 19, 551.
11. Cortés, R.; Palacios, J. M. Muscarinic cholinergic receptor subtypes in the rat brain. I. Quantitative autoradiographic studies. Brain Res. 1986, 362, 227-238.
12. Messer, W. S., Jr.; Ellerbrock, B. R.; Smith, D. A.; Hoss, W. Regional differences in the binding of selective muscarinic antagonists to rat brain: Comparison with minimum energy conformations. J. Med. Chem. 1989, 32, 1164-1172.
13. Buckley, N. J.; Bonner, T. I.; Brann, M. R. Localization of a family of muscarinic receptor mRNAs in rat brain. J. Neurosci. 1988, 8, 4646-4652.
14. Wall, S. J.; Yasuda, R. P.; Hory, F.; Flagg, S.; Martin, B. M.; Ginns, E. I.; Wolfe, B. B. Production of antisera selective for m1 muscarinic receptors using fusion proteins: Distribution of m1 receptors in rat brain. Mol. Pharmacol. 1991, 39, 643-649.
15. Caulfield, M. P.; Higgens, G. A.; Straughan, D. W. Central administration of the muscarinic receptor subtype-selective antagonist pirenzepine selectively impairs passive avoidance learning in the mouse. J. Pharm. Pharmacol. 1983, 35, 131-132.
16. 1 muscarinic antagonist pirenzepine. Psychopharmacology 1987, 93, 470-476.
17. Messer, W. S., Jr.; Thomas, G. J.; Hoss, W. P. Selectivity of pirenzepine in the central nervous system. II. Differential effects of pirenzepine and scopolamine on performance of a representational memory task. Brain Res. 1987, 407, 37-45.
18. 1 muscarinic receptors in representational memory. Neurosci. Lett. 1990, 116, 184-189.
19. Gil, D. W.; Wolfe, B. B. Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclase. J. Pharmacol. Exp. Ther. 1985, 232, 608-616.
20. Fisher, S. K.; Figueiredo, J. C.; Bartus, R. T. Differential stimulation of inositol phospholipid turnover in brain by analogs of oxotremorine. J. Neurochem. 1984, 43, 1171-1179.
21. Fisher, S. K.; Agranoff, B. W. Receptor activation and inositol lipid hydrolysis in neural tissues. J. Neurochem. 1987, 48, 999-1017.
22. Mash, D. C.; Flynn, D. D.; Potter, L. T. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 1985, 228, 1115-1117.
23. Lapchak, P. A.; Araujo, D. M.; Quirion, R.; Collier, B. Binding sites for 3H-AF-DX 116 and effect of AF-DX 116 on endogenous acetylcholine release from rat brain slices. Brain Res. 1989, 496, 285-294.
24. Hoss, W.; Messer, W. S., Jr.; Monsma, F. J., Jr.; Miller, M. D.; Ellerbrock, B. R.; Scranton, T.; Ghodsi-Hovsepian, S.; Price, M. A.; Balan, S.; Mazloum, Z.; Bohnett, M. Biochemical and behavioral evidence for muscarinic autoreceptors in the CNS. Brain Res. 1990, 517, 195-201.
25. Richards, M. H. Rat hippocampal muscarinic autoreceptors are similar to the M2 (cardiac) subtype - Comparison with hippocampal M1, atrial M2 and ileal M3 receptors. Br. J. Pharmacol. 1990, 99, 753-761.
26. Hammer, R.; Giraldo, E.; Schiavi, G. B.; Monferini, E.; Ladinsky, H. Binding profile of a cardioselective muscarine receptor antagonist, AF-DX 116, to membranes of peripheral tissues and brain in the rat. Life Sci. 1986, 38, 1653-1662.
27. Peralta, E. G.; Ashkenazi, A.; Winslow, J. W.; Smith, D. H.; Ramachandran, J.; Capon, D. J. Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 1987, 6, 3923-3929.
28. Wall, S. J.; Yasuda, R. P.; Li, M.; Wolfe, B. B. Development of an antiserum against m3 muscarinic receptors - Distribution of m3-receptors in rat tissues and clonal cell lines. Mol. Pharmacol. 1991, 40, 783-789.
29. 1 receptors. Bioorg. Med. Chem. Lett. 1992, 2, 781-786.
30. 1 receptor agonists. J. Med. Chem. 1993, 36, 842-847.
31. 1 muscarinic receptor agonists. J. Med. Chem. 1994, 37, 2774-2782.
32. Hirotsu, T.; Katoh, S.; Sugasaka, K.; Seno, M.; Itagaki, T. Binding ability of acetamide oxime with proton, copper (II) and dioxouranium (VI) in aqueous solutions. J. Chem. Soc., Dalton Trans. 1986, 1609.
33. Bandsma, L. In Acetylenic Chemistry, 2nd ed.; Elsevier Press: New York, 1988; pp 217-280.
34. Evans, R. F.; Shannon, J. S. Hydropyrimidies. 4. Catalytic reduction of substituted pyrimidines. J. Chem. Soc. 1965, 1406-1412.
35. Spry, D. O.; Aaron, H. S. 5-Hydroxytetrahydropyrimidine and its 2-methyl homolog. J. Org. Chem. 1966, 31, 3838-3839.
36. Tecle, H.; Lauffer, D. J.; Mirzadegan, T.; Moos, W. H.; Moreland, D. W.; Pavia, M. R.; Schwarz, R. D.; Davis, R. E. A rationale for the design and synthesis of m1 selective muscarinic agonists. Bioorg. Med. Chem. Lett. 1992, 2, 821-826.
37. Tecle, H.; Lauffer, D. J.; Mirzadegan, T.; Moos, W. H.; Moreland, D. W.; Pavia, M. R.; Schwarz, R. D.; Davis, R. E. Synthesis and SAR of bulky 1-azabicyclo[2.2.1]-3-one oximes as muscarinic receptor subtype selective agonists. Life Sci. 1993, 52, 505-511.
38. Brann, M. R.; Buckley, N. J.; Jones, P.; Bonner, T. I. Expression of a cloned muscarinic receptor in A9 L cells. Mol. Pharmacol. 1987, 32, 450-455.
39. Potter, L. T.; Ferrendelli, C. A. Affinities of different cholinergic agonists for the high and low affinity states of the hippocampal M1 muscarine receptors. J. Pharmacol. Exp. Ther. 1989, 248, 974-978.
40. Bujo, H.; Nakai, J.; Kubo, T.; Fukuda, K.; Akiba, I.; Maeda, A.; Mishina, M.; Numa, S. Different sensitivities to agonist of muscarinic acetylcholine receptor subtypes. FEBS Lett. 1988, 240, 95-100.
41. Schwarz, R. D.; Davis, R. E.; Jaen, J. C.; Spencer, C. J.; Tecle, H.; Thomas, A. J. Characterization of muscarinic agonists in recombinant cell lines. Life Sci. 1993, 52, 465-472.
42. Fisher, S. K.; Klinger, P. D.; Agranoff, B. W. Muscarinic agonist binding and phospholipid turnover in brain. J. Biol. Chem. 1983, 258, 7358-7363.
43. Fisher, S. K.; Snider, R. M. Differential receptor occupancy requirements for muscarinic cholinergic stimulation of inositol lipid hydrolysis in brain and in neuroblastomas. Mol. Pharmacol. 1987, 32, 81-90.
44. Periyasamy, S.; Messer, W. S., Jr.; Rocknich, S.; Hoss, W. Alkoxy-1,2,5-thiadiazole derivatives of arecoline stimulate M1 muscarinic receptors coupled to phosphoinositide turnover. Brain Res. 1995, 693, 118-123.
45. Novotny, E. A.; Brann, M. R. In Fourth International Symposium on Subtypes of Muscarinic Receptors; Elsevier Trends Journals: Wiesbaden, FRG, 1989; p 116.
46. Olianas, M. C.; Onali, P.; Neff, N. H.; Costa, E. C. Adenylate cyclase activity of synaptic membranes from rat striatum. Inhibition by muscarinic receptors. Mol. Pharmacol. 1983, 23, 393-398.
47. Lipton, M.; Still, W. C. The multiple minimum problem in molecular modeling. Tree searching internal coordinate conformational space. J. Comput. Chem. 1988, 9, 343-355.
48. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. Macromodel-An integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990, 11, 440.
49. Ojo, B.; Dunbar, P. G.; Durant, G. J.; Nagy, P. I.; Huzl, J. J., III; Periyasamy, S.; Ngur, D. O.; El-Assadi, A. A.; Hoss, W. P.; Messer, W. S., Jr. Synthesis and biochemical activity of novel amidine derivatives as m1 muscarinic receptor agonists. Bioorg. Med. Chem. 1996, 4, 1605-1615.
50. Nordvall, G.; Hacksell, U. Binding-site modeling of the muscarinic m1 receptor - a combination of homology-based and indirect approaches. J. Med. Chem. 1993, 36, 967-976.
51. Wess, J.; Maggio, R.; Palmer, J. R.; Vogel, Z. Role of conserved threonine and tyrosine residues in acetylcholine binding and muscarinic receptor activation. A study with m3 muscarinic receptor point mutants. J. Biol. Chem. 1992, 267, 19313-19319.
52. Bluml, K.; Mutschler, E.; Wess, J. Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic receptors. J. Biol. Chem. 1994, 269, 18870-18876.
53. 1 pharmacophore. J. Med. Chem. 1992, 35, 4011-4019.
54. TRIPOS, Inc., St. Louis, MO, 1994.
55. 1 muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines. J. Med. Chem. 1992, 35, 2274-2283.
56. Grochowski; Jurczac. New synthesis of O-alkylhydroxylamines. Synthesis 1976, 10, 682-684.
57. Farrar, J. R.; Hoss, W.; Herndon, R. M.; Kuzmiak, M. Characterization of muscarinic cholinergic receptors in the brains of copper deficient rats. J. Neurosci. 1985, 5, 1083-1089.
58. Brown, E.; Kendall, D. A.; Nahorski, S. R. Inositol phospholipid hydrolysis in rat cerebral cortical slices: I. Receptor characterisation. J. Neurochem. 1984, 42, 1379-1387.
59. Periyasamy, S.; Hoss, W. Kappa opioid receptors stimulate phosphoinositide turnover in rat brain. Life Sci. 1990, 47, 219-225.
60. Hoss, W.; Woodruff, J. M.; Ellerbrock, B. R.; Periyasamy, S.; Ghodsi-Hovsepian, S.; Stibbe, J.; Bohnett, M.; Messer, W. S., Jr. Biochemical and behavioral responses of pilocarpine at muscarinic receptor subtypes in the CNS. Comparison with receptor binding and low-energy conformations. Brain Res. 1990, 533, 232-238.
61. 3H]dopa in various regions of the brain. J. Neurochem. 1966, 13, 655-669.
62. Wreggett, K. A.; Irvine, R. F. A rapid separation method for inositol phosphates and their isomers. Biochem. J. 1987, 245, 655-660.
63. Lee, N. H.; El-Fakahany, E. E. Allosteric interactions at the m1, m2 and m3 muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 1991, 256, 468-470.
64. Dörje, F.; Wess, J.; Lambrecht, G.; Tacke, R.; Mutschler, E.; Brann, M. R. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 1991, 256, 727-733.
65. Wess, J.; Bonner, T. I.; Dörje, F.; Brann, M. R. Delineation of muscarinic receptor domains conferring selectivity of coupling to guanine nucleotide-binding proteins and second messengers. Mol. Pharmacol. 1990, 38, 517-523.
66. Brooker, G.; Harper, J. F.; Teraski, W. L.; Moylan, R. D. Radioimmunoassay of cyclic AMP and cyclic GMP. Adv. Cycl. Nucleotide Res. 1979, 10, 1-33.
67. 50) of and enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
68. Dewar, M. J. S.; Thiel, W. Ground states of molecules. The MNDO method. Approximations and parameters. J. Am. Chem. Soc. 1977, 99, 4899-4907.
69. Stuart, J. J. P. QCPE no. 455, Bloomington, IN.
70. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stuart, J. J. P. AM1: A new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 1985, 107, 3902-3909.